Erythropoietin Drugs Market Size

Erythropoietin Drugs Market registered a profitable valuation of USD 10.90 billion in 2024 and is projected to register USD 20.04 billion in 2037, expanding at a CAGR of 4.8% during the forecast period, i.e., 2025-2037. In 2025, the industry size of erythropoietin drugs is evaluated at USD 11.42 Billion.

The primary growth driver of the erythropoietin drugs market is the increasing prevalence of chronic diseases that lead to anemia, such as chronic kidney disease (CKD) and cancer. These conditions often reduce the body’s ability to produce red blood cells, making EPO drugs essential for managing anemia. A hospital-based study on the prevalence of anemia published by the National Library of Medicine (NLM) in 2023, reported that anemia in CKD is prevalent at 14% in the United States, 39.36% in India, 51.5% in China, 43.18% in South Africa, and 79% in Cameroon. Furthermore, the prevalence rises with CKD stage, with overall rates of 22.4%, 41.3%, and 53.9% in stages 3, 4, and 5, respectively.

Moreover, the rising incidence of CKD and cancer is a significant driver for the erythropoietin drugs market. Both conditions are closely associated with anemia, as CKD can impair kidney function, and cancer treatments, such as chemotherapy, can damage bone marrow and decrease red blood cell production. Anemia is prevalent among cancer patients, accounting for more than 40% of cases. This creates a demand for EPO drugs, which help stimulate red blood cell production and manage anemia symptoms, improving the quality of life for patients.